Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sedation - Overview
Sedation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sedation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sedation - Companies Involved in Therapeutics Development
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Melt Pharmaceuticals Inc
Paion AG
Seropeutics LLC
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Prime Pharmaceutical Co Ltd
Sedation - Drug Profiles
(ketamine + midazolam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclopofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexmedetomidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EL-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HR-7056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XK-568b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News & Press Releases
Feb 09, 2021: Melt Pharmaceuticals completes phase 1 study for sublingual, non-opioid pain and sedation drug candidate
Jan 28, 2021: Acacia pharma launches BYFAVO(remimazolam) in the United States for procedural sedation in adults undergoing medical procedures lasting 30 minutes or less
Jan 28, 2021: CHMP recommended granting a marketing authorisation for Byfavo (remimazolam) for procedural sedation
Dec 15, 2020: Acacia Pharma announces amendment of its investment agreement with Cosmo Pharmaceuticals for BYFAVO
Dec 14, 2020: tiol Food and Drug Administration approves the marketing of cyclopofol injection
Oct 09, 2020: Acacia Pharma completes drawdown from ?25 million loan facility from Cosmo Pharmaceuticals to support US launch of BYFAVO
Oct 06, 2020: Acacia Pharma announces BYFAVO (remimazolam), its newly approved product for procedural sedation, clears fil hurdle on path to commercial launch in the US
Jul 29, 2020: Melt Pharmaceuticals enters the clinical stage of MELT-100 development
Jul 02, 2020: Acacia Pharma announces US FDA approval of BYFAVO (remimazolam) for injection for the induction and maintence of procedural sedation
Feb 13, 2019: Melt Pharmaceuticals improves patent estate for sublingual non-opioid pain and sedation formulations
Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intrasal Study Required
Oct 18, 2017: Remimazolam phase III Broncoscopy data to be presented at the Chest Annual Meeting 2017
Sep 28, 2017: European Patent Office Grants Formulation Patent For Remimazolam In The EU
Jun 28, 2017: Paion reports positive headline data in U.S. Phase III trial with Remimazolam for procedural sedation undergoing Bronchoscopy
Mar 28, 2017: Paion successfully completes patient recruitment in U.S. Phase III study with Remimazolam for procedural sedation during Bronchoscopy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Sedation, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Sedation, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2021
Sedation - Pipeline by Melt Pharmaceuticals Inc, 2021
Sedation - Pipeline by Paion AG, 2021
Sedation - Pipeline by Seropeutics LLC, 2021
Sedation - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2021
Sedation - Pipeline by Sichuan Prime Pharmaceutical Co Ltd, 2021
Sedation - Dormant Projects, 2021
Sedation - Discontinued Products, 2021